BioView Ltd. (TASE:BIOV) reports that Massachusetts General Hospital in Boston is using the company's screening system to develop an application for a cancer diagnostics test for Circulating Tumor Cells.
New studies by US doctors found that the test, which is similar to a blood test, can discover single tumor cells in the bloodstream. This is a breakthrough in personalized medicine and in the use of new cancer medications. BioView believes that this research breakthrough could boost sales of its screeing system.
BioView develops automated microscopy testing products for screening cancer cells. The company has developed blood, urine, bone marrow, and amniotic fluid tests.
BioView's share price rose 2.6% by midday to NIS 2.21, giving a market cap of NIS 28 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011